Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: A large cross-sectional study of HIV-infected patients on antiretroviral therapy

HIV Medicine

Volumn 14, Issue 3, 2013, Pages 153-160

  Gianotti, N ^a   Galli, L ^a   Bocchiola, B ^a   Cahua, T ^a   Panzini, P ^a   Zandona D ^a   Salpietro, S ^a   Maillard, M ^a   Danise, A ^a   Pazzi, A ^a   Lazzarin, A ^a,b   Castagna, A ^a  

^a San Raffalele Scientific Institute   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Adherence; Antiretroviral therapy; CD4 cell count; Health status; HIV RNA

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; AGE DISTRIBUTION; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG DOSE REGIMEN; FEMALE; HEALTH STATUS; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PATIENT COMPLIANCE; PILL; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SELF REPORT; SEX DIFFERENCE; VIREMIA; VISUAL ANALOG SCALE;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARBAMATES; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; ITALY; LAMIVUDINE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEVIRAPINE; OLIGOPEPTIDES; ORGANOPHOSPHATES; ORGANOPHOSPHONATES; OXAZINES; PYRIDINES; QUESTIONNAIRES; SELF REPORT; SULFONAMIDES; VIRAL LOAD;

EID: 84873258967     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2012.01046.x     Document Type: Article

References (25)

1. Ammassari A, Trotta MP, Murri R etal. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002; 31 (Suppl 3): S123-S127.
2. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 2009; 48: 484-488.
3. Airoldi M, Zaccarelli M, Bisi L etal. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010; 13: 115-125.
4. Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 2010; 24: 2835-2840.
5. Eron JJ, Feinberg J, Kessler HA etal. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis 2004; 189: 265-272.
6. Maggiolo F, Ripamonti D, Arici C etal. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials 2002; 3: 371-378.
7. Trotta MP, Ammassari A, Cozzi-Lepri A etal. Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. AIDS 2003; 17: 1099-1102.
8. Flandre P, Peytavin G, Meiffredy V etal. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial. Antivir Ther 2002; 7: 113-121.
9. Murri R, Ammassari A, Gallicano K etal. Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr 2000; 24: 123-128.
10. Antinori A, Cozzi-Lepri A, Ammassari A etal. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther 2004; 9: 291-296.
11. Ruelle J, Jnaoui K, Lefevre I, Lamarti N, Goubau P. Comparative evaluation of the VERSANT HIV-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the quantification of HIV-1 plasma viral load. J Clin Virol 2009; 44: 297-301.
12. Troppan KT, Stelzl E, Violan D, Winkler M, Kessler HH. Evaluation of the new VERSANT HIV-1 RNA 1.0 Assay (kPCR) for quantitative detection of human immunodeficiency virus type 1 RNA. J Clin Virol 2009; 46: 69-74.
13. Molina JM, Andrade-Villanueva J, Echevarria J etal. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53: 323-332.
14. Nelson M, Girard PM, Demasi R etal. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data. J Antimicrob Chemother 2010; 65: 1505-1509.
15. Barfod TS, Sorensen HT, Nielsen H, Rodkjaer L, Obel N. 'Simply forgot' is the most frequently stated reason for missed doses of HAART irrespective of degree of adherence. HIV Med 2006; 7: 285-290.
16. Grierson J, Koelmeyer RL, Smith A, Pitts M. Adherence to antiretroviral therapy: factors independently associated with reported difficulty taking antiretroviral therapy in a national sample of HIV-positive Australians. HIV Med 2011; 12: 562-569.
17. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004; 36: 808-816.
18. Parienti JJ, Massari V, Reliquet V etal. Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study. AIDS 2007; 21: 2217-2222.
19. Godin G, Côté J, Naccache H, Lambert LD, Trottier S. Prediction of adherence to antiretroviral therapy: a one-year longitudinal study. AIDS Care 2005; 17: 493-504.
20. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials 2004; 5: 74-79.
21. Liu H, Golin CE, Miller LG etal. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134: 968-977.
22. Vervoort SC, Borleffs JC, Hoepelman AI, Grypdonck MH. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS 2007; 21: 271-281.
23. Clotet B, Carmena J, Pulido F, Luque I, Rodriguez-Alcantara F. COL30494 Cohort Study Members. Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients. HIV Clin Trials 2004; 5: 33-39.
24. Murri R, Marcotullio S, Lupoli P, von Schloesser F. Is 'once-daily' regimen a key strategy for improving adherence to antiretroviral regimens? J Acquir Immune Defic Syndr 2006; 42: 259-260.
25. Briongos Figuero LS, Bachiller Luque P, Palacios Martin T, Gonzalez Sagrado M, Eiros Bouza JM. Assessment of factors influencing health-related quality of life in HIV-infected patients. HIV Med 2011; 12: 22-30.